๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer

โœ Scribed by Philip A. Philip; Michelle R. Mahoney; Kyle D. Holen; Donald W. Northfelt; Henry C. Pitot; Joel Picus; Patrick J. Flynn; Charles Erlichman

Book ID
112066901
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
825 KB
Volume
118
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase 2 study of erlotinib in patients w
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
โœ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti